Slaughter and May is advising GlaxoSmithKline (GSK) on its strategic collaboration with the Aspen Group (Aspen) in Japan.  The transaction involves GSK and Aspen contributing certain branded products and capital to the collaboration. GSK will also contribute to the collaboration the right to commercialise authorised generic versions of a number of its products once the exclusivity period for those products has expired. The transaction is expected to close by the end of 2015.

Slaughter and May is working as a team with Nagashima Ohno & Tsunematsu, which is advising GSK as its Japanese counsel.

CONTACTS

Corporate and Commercial: Richard Smith (partner), Jeremy Chew (associate), Claire Jackson (associate); Intellectual Property: Susie Middlemiss (partner), Sarah Mateen (associate); Tax: Dominic Robertson (partner); Competition: Jordan Ellison (partner), Stephen Heagney (associate)